Skip to main content
. 2023 Jun 2;24(1):63. doi: 10.1186/s10194-023-01585-2

Table 4.

Adverse effects during the follow-up

Adverse effect [n (%)] M3 (n = 162) M6 (n = 134)
Any 33 (20.4) 19 (14.2)
Constipation 16 (9.9) 16 (9.9)
Injection site reaction 6 (3.7) 1 (0.6)
Dizziness 3 (1.8) 1 (0.6)
Hypertension 2 (1.2) 0
General discomfort 2 (1.2) 1 (0.6)
Unsteadiness 1 (0.6) 0
Hypotension 1 (0.6) 0
Headache worsening 1 (0.6) 0
Transient facial erythema 1 (0.6) 0